GlassScriptPhysician profile
Morodak Meas
NPI 1124252366
$1,908.28
in general payments reported to CMS, 2019-2025
27 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $114 · 2021: $207 · 2022: $167 · 2023: $245 · 2024: $418 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $409.78 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $287.10 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $194.17 | 2019-2025 | Wainua |
| Boston Scientific Corporation | $124.01 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.53 | 2021-2022 | |
| Novo Nordisk INC | $97.73 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $83.87 | 2019-2025 | Rotateq, Capvaxive, Gardasil 9 |
| Abbott Laboratories | $73.74 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $45.61 | 2020 | |
| Mannkind Corporation | $45.04 | 2019-2023 | Afrezza |
| Pfizer INC. | $41.04 | 2023-2024 | |
| Sanofi Pasteur INC. | $39.87 | 2019-2023 | |
| Amgen INC. | $34.13 | 2025 | Krystexxa |
| Sage Therapeutics, LLC | $33.99 | 2025 | Zurzuvae |
| Gilead Sciences, INC. | $31.90 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.31 | 2024 | |
| Abiomed | $30.24 | 2025 | |
| Cranial Technologies, INC | $30.12 | 2020-2021 | |
| Abbvie INC. | $23.60 | 2019 | |
| Dexcom, INC. | $22.45 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $21.17 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.35 | 2024 | Lifevest |
| Allergan, INC. | $18.82 | 2020 | |
| Zealand Pharma US, INC. | $18.75 | 2022 | |
| Electromed, INC. | $18.27 | 2024 | Smartvest |
| Lundbeck LLC | $17.12 | 2024 | Rexulti |
| Valeritas, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morodak Meas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.